New Hope for Vitiligo: EMA Backs Patient-Focused Drug Trial

MELBOURNE, Australia – April 24, 2026 – Millions of individuals living with vitiligo, a skin disorder causing progressive loss of pigment, received a significant boost of hope today. Australian pharmaceutical firm CLINUVEL announced it has received final scientific advice from the European Medicines Agency (EMA) for its upcoming pivotal Phase III trial of SCENESSE® (afamelanotide), paving a clear regulatory path for a potential new systemic treatment.

The EMA’s guidance is notable not just for its approval of the study design, but for its pioneering patient-centric approach. The agency will evaluate the drug's effectiveness based on a “totality of evidence,” a comprehensive framework that places a patient’s own perception of improvement on par with traditional clinical metrics. This decision marks a potential paradigm shift in how treatments for chronic, visually impactful conditions are developed and approved.

A Landmark Shift Towards Patient Experience

Vitiligo affects an estimated 0.5% to 2% of the global population, or up to 100 million people, and is characterized by white patches of skin resulting from the destruction of pigment-producing cells called melanocytes. While not life-threatening, the disease carries a profound psychosocial burden, frequently leading to social anxiety, depression, and a severely diminished quality of life. This impact is often most acute for individuals with darker skin tones, where the contrast between pigmented and depigmented skin is more pronounced.

Recognizing this, the EMA has specifically emphasized that the patient's own assessment of change will play a crucial role in the final evaluation of SCENESSE®. The upcoming CUV107 study will integrate five different patient and physician surveys to capture these Patient Reported Outcomes (PROs). This moves beyond simply measuring the size of repigmented areas to understanding if the treatment provides a meaningful, visible improvement from the patient's perspective.

The EMA advised that patients with darker skin tones (Fitzpatrick skin types IV-V-VI) would be the first to benefit from a systemic therapy, acknowledging the high visibility of the disease in these groups. The trial will use centralized photographic review to objectively assess repigmentation, but the inclusion of PROs ensures the human element of the disease is not lost in the data.

Redefining the Regulatory Playbook

The EMA's endorsement of a “totality of evidence” approach is the result of over a year of intensive dialogue between CLINUVEL and the agency's Scientific Advice Working Party (SAWP). This regulatory strategy signals a move away from relying on a single, rigid primary endpoint and towards a more holistic evaluation.

“The dialogue took one year but eventually resulted in a one-off position taken by the Agency, who are now fully across the SCENESSE® program and possible expected outcomes in vitiligo,” said Dr. Emilie Rodenburger, CLINUVEL’s Director of Global Clinical Affairs, in a statement. “A major step forward was the request by the SAWP to access photographic changes of vitiligo patients receiving treatment, which demonstrated visual improvement in pigmentation.”

The primary endpoint for the study will be T-VASI50, which measures the proportion of patients who achieve at least 50% repigmentation of their total body surface area. However, the EMA has indicated this will be indicative, not solely determinative, of efficacy. This flexibility allows regulators to consider a wider array of data, including secondary endpoints like facial repigmentation (F-VASI75) and the crucial patient feedback, when making a final decision.

This nuanced approach could set a new precedent for drug development in dermatology and other fields where quality of life and patient perception are as important as clinical measurements. It provides a more adaptable pathway for therapies addressing complex conditions with significant subjective impact.

A Strategic Leap into a Competitive Market

For CLINUVEL, this milestone represents a strategic expansion from a niche rare disease leader into the much larger, multi-billion-dollar global vitiligo market. The company’s lead drug, SCENESSE®, is already approved in Europe, the US, and other regions as the world’s first systemic photoprotective therapy for patients with erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe light intolerance.

SCENESSE® is a synthetic version of a naturally occurring hormone that stimulates the production of melanin, the skin’s dark pigment. Its mechanism is a logical fit for treating vitiligo, where the goal is to restore lost pigment. The CUV107 study will evaluate SCENESSE® as an adjunct to narrowband ultraviolet B (NB-UVB) phototherapy, a current standard of care, to see if the combination can produce superior repigmentation compared to phototherapy alone.

However, CLINUVEL is entering a dynamic and increasingly competitive field. The vitiligo treatment landscape was recently transformed by the approval of Incyte’s Opzelura, a topical JAK inhibitor that has become the first FDA-approved therapy for repigmentation. With other major pharmaceutical players like Pfizer investigating systemic JAK inhibitors and a pipeline of other novel treatments emerging, the market is poised for significant growth, projected to exceed $2 billion by 2035.

CLINUVEL’s SCENESSE® aims to carve out a unique position as a systemic, non-immunosuppressive treatment. By stimulating the body’s natural pigmentation process rather than modulating the immune system, it offers a differentiated approach that could be particularly valuable for patients with extensive disease who are not adequately served by topical creams.

The Road Ahead

With the regulatory framework now clearly defined, CLINUVEL is preparing to launch the CUV107 study in the second half of 2026. The trial will enroll 300 adult and adolescent patients with non-segmental vitiligo, representing the final, pivotal step before a potential marketing authorisation application can be submitted to the EMA.

From an investor standpoint, the EMA’s guidance significantly de-risks the program and validates the company’s long-term strategy to leverage its expertise in photomedicine for a broader patient population. The successful outcome of the year-long discussions provides a level of certainty that is rare in late-stage drug development.

As the company prepares for this crucial trial, the focus now shifts to execution. For the millions of people worldwide hoping for a more effective and convenient treatment to restore their skin color and confidence, the commencement of this study cannot come soon enough.